Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

EXOPLEXs

680 views

Published on

EXOPLEX is a novel drug delivery system of nanoscale dimensions with features of improved cellular uptake, cell
targeting and low toxicity, as well as the ability for further functionalisation. Currently we are using EXOPLEXs
to transfect or introduce genetic material into difficult-to-transfect cell lines and evaluating its commercial
viability as a research reagent. In this aspect, EXOPLEXs would be a one-step transfection reagent with the aim
of improved transfection efficiency compared to conventional non-viral transfection methods.

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

EXOPLEXs

  1. 1. P I : A / P G i o r g i a P A S T O R I N ǀ E L : W e i J i a n g G O H ǀ T M : S h u i Z O U ǀ M e n t o r : D r J u W e i W O N G E X O P L E X s Ta i l o r i n g Yo u r Tr a n s f e c t i o n N e e d s
  2. 2. EXOPLEXs An Nanoparticle System Drug cargo Enlarged View EXOPLEXs • Small Molecules • Peptides • Plasmid Value Proposition Drug Delivery
  3. 3. EXOPLEXs An Nanoparticle System Enlarged View EXOPLEXs High drug loading capacity Value Proposition Drug Delivery
  4. 4. Targeted Drug Delivery Tumour cellsTumour cells delivered with Anti-cancer Drug Cargo Intravenous Injection Tumour SiteDrug loaded EXOPLEXs Targeting only Tumour Cells Reduced Tumour size Value Proposition Drug Delivery
  5. 5. Therapeutics 1 Cosmeceutical / Dermatological Solutions 2 Transfection Kit for Difficult-to-transfect cell types For Research Use 3 What we thought 5 What we brainstorm during LLP What we thought Market Segments
  6. 6. Research Assistants PhDs Post Doctoral Research Fellows Principle Investigators Companies Industry Liaison Office Interviews Medicine Pharmacy Engineering Chemistry Commercial Interviews (by field) 6 Interviews Total 33
  7. 7. Most Regulatory Oversight Longest route to market Most Requirement for data Least Regulatory Oversight Shortest route to market Least Requirement for data Transfection Kit for Difficult-to-transfect cell types For Research Use Cosmeceutical / Dermatological Solutions Therapeutics 1 2 3 Continue in the background No interest Beachhead Strategy What we found Market Segments
  8. 8. Transfection Kit for Difficult-to-transfect cell types For Research Use Cosmeceutical / Dermatological Solutions Therapeutics 1 2 3 Continue in the background No interest Beachhead Strategy 8 Big Pharma Therapeutics Company Cosmetic Companies Laboratory End UsersCustomers From B2B to B2C What we found Customers
  9. 9. EXOPLEXs Genetic Material Enlarged View EXOPLEXs • Plasmid • siRNA • shRNA Beachhead Strategy Transfecting Difficult-to-Transfect Cells
  10. 10. EXOPLEXs Genetic Material Enlarged View EXOPLEXs Beachhead Strategy Transfecting Difficult-to-Transfect Cells
  11. 11. 11 Single Step Transfection Target cells (Eg. Fat cells, Blood Cells, Skin cells, Stem Cells) Cells expressing GFP EXOPLEXs With plasmid Transfecting Difficult-to-Transfect Cells Beachhead Strategy Transfecting Difficult-to-Transfect Cells * GFP: Green Fluorescent Protein
  12. 12. 12 CAGR 7.1% from 2009 to 2016 What we found Market Sizing $183.6 Million Transfection Reagents Market Transfection Research Market $30 Billion Drug Delivery Market $348 Million 1. Frost & Sullivan, 2010, Global Transfection Markets. 2. Frost & Sullivan, 2016, Nanotechnology for Effective Drug Delivery
  13. 13. 13 EaseofUse Efficacy *size of circle: Cost Effectiveness EXOPLEXs Lipofectamine Effectene PEI Electroporation Combination of methods Viral delivery Transfection Research What we found Competitive Landscape
  14. 14. 14 EXOPLEXs Sales (Transfection Kit) Licensing What we thought What we found Licensing EXOPLEXs Lab End UsersResearch Kit Companies Research Kit Companies What we found Business Model
  15. 15. 15 What we found Channels Direct Sales Distributorships Time Collaborations • Efficacy Data, Publications • Product Support • Small scale manufacture • Bespoke services • OEM • Sales force
  16. 16. 1. Targeting & Minimal collateral damage 2. Improved cell delivery 3. Biocompatible 4. Avert patent cliff 1. Universities 2. Pharma companies 3. Therapeutic companies 4. Drug Delivery companies 5. Cosmetic companies Production of: • Efficacy data • Safety data • Intellectual property • Trained laboratory users • Raw materials • Equipment • Universities • Government (Grants) 1. In-house development of single chemotherapeutic 2. In-house development of EXOPLEXs as transfection agent 3. In-house development of EXOPLEXs as a cosmetic agent 4. Licencing for other uses Value driven: 1. R & D costs 2. Trained personnel costs 3. Raw materials 4. Patent development 1. Outreach via publications, workshops and conferences 2. Continuous feedback with interested parties to fine tune EXOPLEXs platform to their use • Single sided niche market • B2B model When we first started Business Model Canvas
  17. 17. Key Partners Key Activities Value Proposition Key Resources Customer Relationships Channels Customer Segments Cost Structure Revenue Streams 1. Publications 2. Efficacy data 3. Comparison data • Transfecting Difficult-to- Transfect cells • Improved user experience • Increased research efficiency • Co- development/ collaboration with innovators & early adopters • Direct • Academic and research labs focusing tissue labs • Primary cell lines • Skin, fat, neurons, stem cells • Intellectual Property • Trained lab personnel • Keep costs down, asset light by staying affiliated to NUS • Currently exploring other revenue streams, ie direct sales and co- development with other companies. After 10 weeks Business Model Canvas
  18. 18. 18 Transfecting difficult to transfect Cells Drug Delivery Clinical Applications Gene Therapy Peptide-based Delivery Small Molecule Delivery Beachhead Strategy • Revenue Generation • Direct sales • Licensing • Distributorships Long Term Strategy • Revenue Generation • Licensing • Co-development 2016: $183.6 Million1 2020: $30 Billion 1. Frost & Sullivan, 2010, Global Transfection Markets. 2. Frost & Sullivan, 2016, Nanotechnology for Effective Drug Delivery Time (Years) Difficulty Roadmap for the Future
  19. 19. 19 What we have now What we will do next 1. Provisional Patent 2. Efficacy data 1. More R & D for MVP 2. Publications 3. Find potential Collaborators (Labs) 4. Applications for Grants (POC) Next Steps
  20. 20. 20 Wei Jiang GOH Principle Investigator Department of Pharmacy Entrepreneurial Lead PhD-MBA Student Department of Pharmacy Team Member PhD Student Department of Pharmacy A/P Giorgia PASTORIN Shui ZOU The Team Team Mentor Dr Ju Wei Wong
  21. 21. 21 Thank You E X O P L E X s
  22. 22. E X O P L E X s Strategy Transfection Kit • Difficult-to-transfect cells Drug delivery platform • Small molecules • Peptides • Genetic material Small Scale Manufacturing Licensing Licensing Co-Development Direct Sales Sales & Distributorship Research Lab End Users Research Reagent Companies Generics Companies Delivery to difficult to reach cells • Neurodegenerative diseases • Diabetes Partnership with emerging biotech companies • Potential NDAs Search for off-patent drug for averting patent cliff Pharma Companies Biotech Companies Strategy Revenue Model Customer *Beachhead strategy 2020: $30 Billion 2016: $183.6 Million *Frost & Sullivan

×